Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M29,082Revenue (TTM) $M2,954Net Margin (%)12.5Altman Z-Score4.4
Enterprise Value $M31,246EPS (TTM) $1.6Operating Margin %21.6Piotroski F-Score6
P/E(ttm)79.2Beneish M-Score-2.5Pre-tax Margin (%)18.5Higher ROA y-yN
Price/Book3.410-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsY
Price/Sales9.85-y EBITDA Growth Rate %35.4Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow49.5y-y EBITDA Growth Rate %28.8ROA % (ttm)2.8Higher Current Ratio y-yN
Dividend Yield %--PEG2.3ROE % (ttm)4.5Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M224ROIC % (ttm)4.1Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJohn Paulson 2016-09-30 Reduce-0.05%$117.64 - $137.66
($128.72)
$ 129.871%Reduce -15.04%227,700
ALXNJoel Greenblatt 2016-09-30 Reduce-0.02%$117.64 - $137.66
($128.72)
$ 129.871%Reduce -19.95%46,797
ALXNRon Baron 2016-09-30 Reduce-0.01%$117.64 - $137.66
($128.72)
$ 129.871%Reduce -28.90%44,260
ALXNJohn Paulson 2016-06-30 Add0.14%$111.89 - $161.38
($141.84)
$ 129.87-8%Add 70.48%268,000
ALXNJoel Greenblatt 2016-06-30 Add0.07%$111.89 - $161.38
($141.84)
$ 129.87-8%Add 447.16%58,459
ALXNRon Baron 2016-06-30 Add$111.89 - $161.38
($141.84)
$ 129.87-8%Add 11.26%62,249
ALXNDodge & Cox 2016-06-30 Sold Out $111.89 - $161.38
($141.84)
$ 129.87-8%Sold Out0
ALXNJohn Paulson 2016-03-31 Buy 0.17%$127.91 - $190.75
($147.61)
$ 129.87-12%New holding157,200
ALXNJoel Greenblatt 2016-03-31 Buy 0.02%$127.91 - $190.75
($147.61)
$ 129.87-12%New holding10,684
ALXNDodge & Cox 2016-03-31 Buy $127.91 - $190.75
($147.61)
$ 129.87-12%New holding1,820
ALXNRon Baron 2016-03-31 Reduce$127.91 - $190.75
($147.61)
$ 129.87-12%Reduce -8.54%55,950
ALXNRon Baron 2015-12-31 Add0.02%$152.66 - $191.88
($175.28)
$ 129.87-26%Add 87.52%61,177
ALXNDavid Swensen 2015-09-30 Sold Out -16.37%$145.6 - $207.84
($182.41)
$ 129.87-29%Sold Out0
ALXNRon Baron 2015-09-30 Reduce-0.03%$145.6 - $207.84
($182.41)
$ 129.87-29%Reduce -53.24%32,624
ALXNMario Gabelli 2015-09-30 Sold Out $145.6 - $207.84
($182.41)
$ 129.87-29%Sold Out0
ALXNDavid Swensen 2015-06-30 Buy 16.37%$155.01 - $190.92
($172.58)
$ 129.87-25%New holding319,273
ALXNJoel Greenblatt 2015-06-30 Sold Out -0.03%$155.01 - $190.92
($172.58)
$ 129.87-25%Sold Out0
ALXNRon Baron 2015-06-30 Add0.02%$155.01 - $190.92
($172.58)
$ 129.87-25%Add 69.48%69,764
ALXNMario Gabelli 2015-06-30 Buy $155.01 - $190.92
($172.58)
$ 129.87-25%New holding1,415
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 129.87-28%Reduce -72.94%23,261
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDDirector 2017-01-10Sell100$144.99-9.31view
BELL LEONARDDirector 2017-01-09Sell40,065$138.48-5.05view
PARVEN ALVIN SDirector 2017-01-05Sell22,659$138.35-4.96view
Moriarty John BEVP & General Counsel 2016-12-12Sell1,044$118.6110.86view
Thiel CarstenEVP, Chief Commercial Officer 2016-12-09Sell2,308$1301.15view
Wagner Heidi LSVP, Global Government Affairs 2016-11-14Sell59$115.114.24view
BELL LEONARDDirector 2016-11-04Sell37,317$140.38-6.33view
BELL LEONARDDirector 2016-10-31Sell1,634$135.3-2.82view
Thiel CarstenEVP, Chief Commercial Officer 2016-10-14Sell4,584$120.289.32view
Thiel CarstenEVP, Chief Commercial Officer 2016-10-03Sell29$122.417.42view

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016 
Spiros 'Sig' Segalas' Capital Appreciation Fund 2nd Quarter Commentary Nov 07 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 

More From Other Websites
[$$] Drugmakers alarmed by Trump pricing threat Jan 14 2017
ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... Jan 13 2017
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 13 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion... Jan 12 2017
Trump takes aim at pharma Jan 12 2017
Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now Jan 11 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jan 11 2017
JPMorgan Makes Big Changes to US Analyst Focus List for January Jan 11 2017
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU Jan 11 2017
ALEXION PHARMACEUTICALS INC Financials Jan 10 2017
Alexion Seeks Expanded Use for Soliris in US and EU Jan 10 2017
Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized... Jan 10 2017
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline Jan 09 2017
Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference Jan 09 2017
Alexion Blood Disorder Meds Wins Orphan Drug Status Jan 09 2017
Alexion CEO: 'We're moving on' from shakeup Jan 09 2017
Bullish and Bearish Reversals in the Market Jan 09 2017
Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders... Jan 09 2017
Alexion Blood Disorder Drug Gets Orphan Designation in U.S. Jan 09 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)